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The role of TNFR family members in regulating cell fate both in the immune system 
and in non-lymphoid tissues has been under extensive research for decades. Moreover, the 
ability of several family members (death receptors) to induce death (mainly via apoptosis) 
represents a promising target for cancer therapy. Many studies have focused mostly on 
death receptors such as TNFRI, Fas and TRAIL-R due to their strong pro-apoptotic potential. 
Yet, cell death can be triggered via non-classical death receptors, and the Lymphotoxin (LT) 
system represents a very good example of such a TNFR subfamily. Here we provide a 
comprehensive review of intracellular signalling pathways and cellular responses to LT-
specific signalling, and compare for the first time the LT system to other TNFRs, such as 
CD40. Our aim is to highlight that non-classical TNFR-TNFL dyads such as the LT system 
demonstrate more complex, cell-type and context-specific capabilities. Understanding these 
complexities will permit a better understanding of the biological mechanisms via which non-














AP-1: activator protein-1 
APRIL: a proliferation-inducing ligand 
BAFF: B-cell activating factor belonging to the TNF family 
CLL: chronic lymphocytic leukaemia  
DD: death domain  
DR: death receptor 
DcR: decoy receptor  
DIF: differentiation-inducing factor 
Fas: Fibroblast-associated cell-surface 
LT: Lymphotoxin 
LIGHT: Lymphotoxin-like exhibits Inducible expression and competes with herpes simplex 
virus Glycoprotein D for HVEM, HVEM being a receptor expressed on T lymphocytes  
NF-B: nuclear factor kappa B  
NGF: nerve growth factor  
HVEM: herpes-virus entry mediator  
IFN-γ: Interferon-gamma 
JNK: c-Jun N-terminal kinase 
RANK: receptor activator of nuclear factor-kB 
TF: Transcription factor 
TNF: tumour necrosis factor 
TNFα: tumour necrosis factor-alpha 
TNFSF: TNF superfamily  
TNFL: TNF ligand 
TNFR: TNF receptor 
TRAF: TNFR-associated factor  
TRAIL: TNF-related apoptosis-inducing ligand 
TRAIL-R: TRAIL receptor  
TL1A: TNF-like molecule 1A  
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1. The discovery of the Tumour Necrosis Factor (TNF) and 
Lymphotoxin (LT) proteins  
The first indirect evidence for the existence of the tumour necrosis factor (TNF) 
family originates from experiments involving Coley’s mixed toxins, which were discovered in 
the late 1800s. Coley’s toxins consisted of a cocktail of dead bacteria and this toxic mixture 
was found to cause the regression of human sarcomas. The hypothesis was that the 
immune system needs a local trigger, such as that achieved by pathogens, which mediates 
the recruitment of immunocytes in order to attack tumour cells. Decades later, and in line 
with Coley’s discovery, Gratia and colleagues found that administration of bacterial culture 
filtrates (consisting of E.coli and other bacterial types) led to liposarcoma regression in 
guinea pigs. In 1943, Shear and colleagues demonstrated that isolated endotoxins from 
Gram-ve bacterial lipopolysaccharide (LPS) were able to cause haemorrhagic necrosis in 
transplanted murine sarcomas. It was later suggested that the endotoxin-induced 
haemorrhagic necrosis in transplanted tumours was not due to direct cytotoxicity to 
tumours, but occurred by indirect mechanisms that resulted in hypotension, leading to 
vascular collapse and ischemia, thus causing tumour cell anoxia and ultimately cell death. A 
decade later, O’Malley and colleagues reported that administration of this endotoxin mixture 
could induce necrosis to tumour-bearing mice and this factor was formally named Tumour 
Necrosis Serum (TNS). The effectiveness of TNS was further confirmed in vivo and Carswell 
renamed this as Tumour Necrosis Factor (TNF), a ligand that appeared toxic towards 
malignant cells (1), now referred to as TNFα. A series of initial investigations carried out 
both in vitro and in vivo demonstrated the pro-apoptotic potential of TNFα and as the 
administration of recombinant TNFα in tumour-bearing mice resulted in anti-tumour 
responses, these observations rendered TNF a promising anticancer agent.  
Soon after the identification of TNFα, a similar TNF-like factor was discovered and 
named TNFβ which was later renamed Lymphotoxin-alpha (LTα), following its discovery as a 
protein secreted by T lymphocytes after recognition of host virus infection and of tumour 
antigens. Officially the two ligands were characterised when the coding sequences for both 
TNFα and LTα were isolated in the 1980s. The TNFα and LTα proteins are structurally and 
functionally closely related molecules but they demonstrate differential functional outcomes 
on several human cell lines (discussed in detail in subsequent sections). TNFα and LTα are 
now classified into a group of cytokines which have critical functional importance in 
immunity, inflammation, cytodifferentiation and apoptosis and represent the archetypal 




members of the group of proteins that now constitutes the tumour necrosis factor 
superfamily (TNFSF).  
 
2. The TNF ligands (TNFLs) and TNF Receptors (TNFRs)   
The TNFSF consists of a large and complex network of ligands (TNFLs) and receptors 
(TNFRs) and each subgroup of the family may function in distinct ways, based on their 
signalling capacity and their ability to regulate specific gene expression and subsequently 
cell fate. By means of signalling triggered via interactions of these receptors with their 
cognate ligand(s), TNFRs play a critical role in cellular homeostasis and have multifunctional 
roles ranging from promotion of cell growth or induction of differentiation, to cytotoxicity by 
activation of cell death (mainly apoptosis). The members of TNFLs and TNFRs are 
summarised in Table 1 with additional information on their cellular origins and recruited 
intracellular proteins (see also subsequent sections). Whilst, to date, 18 ligands and 29 
receptors have been identified, in this review we will mainly focus on receptors and ligands 
of the Lymphotoxin (LT) system, and compare them with other closely related TNFSF 
systems that share structural and particularly functional similarities. As described above, the 
discovery of LTα came shortly after the discovery of TNFα. Both ligands are able to interact 
with both TNFR –I and –II receptors, albeit with different affinities. Unlike other TNFRs such 
as Fas, TRAIL-R or CD40 which almost exclusively have a single cognate ligand, the LT 
system is far more complex with ligands LTα, LTβ, LTα1β2, LTα2β1, and LIGHT being able 
to interact with the two main transmembrane receptors LTβR and HVEM, the TNFRs –I and 
–II as well as the soluble receptor DcR3 (however the DcR3 receptor will not be discussed in 
this review).  
 
2.1 TNFLs 
TNFLs are type II transmembrane proteins that contain an intracellular N-terminus 
and extracellular C-terminus with the C-terminus region characterised by a conserved TNF 
homology domain (THD) (2, 3). TNFα is expressed in full-length on the cell surface as a 
26kDa membrane ligand (mTNFα) and as a 17kDa soluble cytokine (sTNFα) after shedding. 
By contrast, LTα is always shed as a soluble cytokine, yet LTβ is expressed only in a 
membrane-bound form, as the latter does not contain a cleavage site. LTα and LTβ can 
assemble together and form two membrane bound complexes of LTαβ; the LTα1β2 complex 




consists of a single ββ and two unique αβ sites and exhibits high affinity to LTβR; LTα2β1 on 
the other hand binds to TNFR –I and TNFR –II, but with less affinity to LTβR. LIGHT, also 
known as TNFSF14 or TL4, exists also in either membrane form (29kDa) or a soluble form 
following cleavage by a yet undefined furin-like proteinase and can bind both LTβR and the 
HVEM receptor, but not TNFR –I and TNFR –II (Figure 1).  
 
2.2 TNFRs 
The majority of the TNFRs are type I transmembrane glycosylated proteins with an 
extracellular N-terminus and an intracellular C-terminus, although some TNFRs are type III 
transmembrane proteins (BCMA, TACI, BAFFR and XEDAR (3)). Structurally, TNFRs can be 
divided into three regions; an extracellular domain (ECD), a transmembrane domain (TMD) 
and an intracellular domain (ICD). All TNFRs share a four cysteine-rich domain (CRD) in the 
ECD region, which is responsible for the specificity and affinity of these receptors for their 
cognate ligands.   
In order to initiate TNFR-mediated cell signalling, TNFLs (either in soluble form or in 
membrane-bound form on the surface of an effector cell) induce TNFR clustering, 
aggregation and oligomerisation (cross-linking) on target cells. Signals are generally 
accepted to require trimeric ligands to achieve receptor trimerisation (as shown in Figure 1). 
However, TNFRs may not exist as monomers that trimerise only upon ligand binding; there 
is in fact evidence for the existence of a pre-ligand assembly domain (PLAD) residing within 
the CRD of the receptors, which appears to be critical for the function of the receptor (4). 
Typically, once the receptor is activated, signal transduction is triggered via recruitment of 
adaptor proteins in order to ultimately activate transcription factors such as NF-B or c-Jun 
N-terminal kinase /activator protein-1 (JNK/AP-1) for induction of either proliferation, 
differentiation or, more typically for a large proportion of the TNFSF, cell death (Figure 1). 
The precise nature, timing and extent of adaptor protein recruitment and overall TNFR 
activation are dependent on several factors, such as cell type, cellular context/state, and 
quality of the signal i.e. the strength of ligand-receptor interaction (discussed further in 
subsequent sections). These factors are critical for adaptor protein recruitment and 
intracellular signalling and thus functional outcome.  
 




2.3 TNFR sub-groups 
TNFRs can be divided into three sub-groups based on the specific structural features 
that they contain within their ICD (5). An important characteristic defining the first and more 
classical TNFR group is that the ICD contains a death domain (DD) and this includes TNFRI, 
Fas and TRAIL-Rs (Table 1).  The DD permits signalling initiation via adaptor protein 
recruitment; these adaptor proteins are modular, as they contain a DD (that allows 
interaction with the receptor) as well as a death effector domain (DED). Examples of such 
proteins include the TNFR-associated DD (TRADD) for TNFR-I and Fas-associated DD 
(FADD) for Fas and TRAIL-Rs. The existence of the DED permits induction of apoptotic 
signalling via recruitment of DED-comprising initiator pro-caspases, in particular caspase-8 
and in some cases caspase-10 (5-7).  
The second TNFR group is characterised by the presence of another type of domain 
known as the TRAF-interacting motif (TIM). Receptor activation leads to recruitment of 
TNFR-associated factors (TRAFs), which are zinc RING finger proteins with a C-terminal 
region responsible for receptor binding, and these adaptors mediate recruitment and/or 
activation of downstream signalling pathways, mainly Mitogen Activated Protein Kinases 
(MAPKs) such as p38 and JNK resulting in activation of transcription factors (TFs) such as 
NF-B and AP-1. To date, seven TRAF proteins have been identified and different TNFRs rely 
on distinct signalling pathways mediated by different TRAFs following receptor activation 
(8).  
NF-B is the best studied TF and is a critical transcriptional activator of many genes 
involved in innate and adaptive immunity, inflammatory responses, as well as development 
and maintenance of the immune system. The NF-B family includes Rel (c-Rel), RelA (p65), 
RelB, NF-B1 (p50) and NF-B2 (p52) and activates two pathways; the classical (canonical) 
and alternative (noncanonical) (detailed in Figure 1). In the context of the TNFSF, the 
canonical pathway often mediates inflammatory responses while the noncanonical pathway 
is involved in immune cell proliferation, maturation and is responsible for secondary 
lymphoid organogenesis (reviewed in (9)).  
The third group of TNFRs is characterised by the lack of intracellular signalling 
function, due to the lack of an ICD in their cytoplasmic region. Yet, by maintaining the 
capacity to bind to TNFLs, these receptors act as decoy receptors and attenuate TNFR 
signalling. The best characterised such receptors are the TRAIL decoy receptors TRAIL-R3 
(DcR1) and -R4 (DcR2) (10, 11) (Table 1).  





2.4 Regulation of TNFL and TNFR function by shedding 
Decoy receptors are not the only factor negatively modulating TNFR activation, 
because regulation of receptor signalling involves shedding of both ligands and receptors 
into soluble forms (Figure 2) by the action of a family of metalloprotease known as 
sheddases, and often and this phenomenon is associated with attenuation of ligand-
mediated receptor activation. Such enzymes include disintegrin and metalloproteinase 
(ADAM-17), and the latter is also referred to as TNF-alpha-converting enzyme (TACE) and 
was originally identified for its ability to shed membrane (mTNFα) to soluble ligand (sTNFα) 
(12). Importantly, cleavage of both mTNFRs and mTNFLs into soluble forms limits the 
bioavailability and thus concentrations of TNFLs and their respective TNFRs and this may 
have a direct impact on functional outcome.  
 
3. The TNFα system: ligand-receptor interactions and 
intracellular signalling   
TNFα is either secreted or maintained as a membrane-bound ligand by various 
immune and non-immune cell types including natural killer cells (NK), neutrophils, 
macrophages, monocytes, T cells, mast cells and granulocytes, as well as neurons, 
keratinocytes, smooth muscle cells, fibroblasts, endothelial cells and some malignant non-
lymphoid cell lines (13), where it can activate multiple signalling transduction pathways. 
TNFα, the main ligand for the TNFR –I and –II receptors, is the archetypal pro-inflammatory 
cytokine and is a highly pleiotropic factor that plays critical roles in a variety of physiological 
mechanisms (13, 14). An intriguing feature of the TNFα/TNFR-I/II system is that differential 
receptor expression and/or receptor activation by TNFα can regulate the balance between 
cell survival and apoptosis (15).   
TNFα was found to act as an inducer of apoptotic cell death during the maturation of 
mice thymocytes (16, 17). In vitro, TNFα mainly has either growth inhibitory or cytotoxic 
effects in some normal cell types and in human tumour cells, but in most cases tumour cell 
lines are sensitive to TNFα only when the protein synthesis was inhibited using 
cycloheximide (CHX) (18). TNFα can induce both necrotic and apoptotic cell death in mouse 
fibroblasts in vitro and in vivo (19). In particular, recombinant TNFα causes growth inhibition 
or cytotoxicity in a number of cell lines of human and murine origin such as human 
carcinoma cell lines ME-180 (cervical) and murine fibroblasts (L929). However, not all cells 




respond to TNFα by apoptosis. In fact, normal skin (Detroit 551) and lung fibroblasts (WI-
38) were resistant and their growth was actually stimulated by TNFα (20-22), which is also 
observed in some carcinoma cells types such as those of the bladder, where TNFα can be 
growth-promoting (23). Of note are studies demonstrating that membrane-bound TNFα 
induces stronger signalling via TNFR –I and –II compared with its soluble counterpart, which 
can fundamentally alter the functional outcome of receptor activation (24, 25). Therefore 
TNFα exhibits both cell type- and context-specificity and TNFα-mediated signalling can have 
highly pleiotropic effects.    
TNFRs –I and –II are mainly activated by TNFα although receptor ligation can be 
induced by soluble LTα3 (due to its highly homologous structure to TNFα) and by LTα2β1 
(see also following sections). TNFRI is constitutively expressed on most nucleated cell types 
but is predominantly found on cells of epithelial and fibroblast origins. Overall, TNFRI has a 
greater abundance than TNFRII, with TNFRII mainly expressed on monocytic, lymphocytic, 
myeloid, hematopoietic, endothelial and neuronal cells. During inflammation, both TNFRI 
and TNFRII receptors can be quickly shed into soluble receptors believed to be important in 
down-regulating the inflammatory effects of TNFα and these sTNFRs have been detected in 
human urine and blood serum of cancer patients (26).  
Activation of TNFR –I and –II induces distinct signalling pathways; for instance, it 
has been demonstrated that the stimulation of individual TNFR –I or –II on mouse 
thymocytes and cytotoxic T cell line CT-6 by murine TNF (but not human TNF) induced 
differential effects in these cells (27). Agonistic antibodies specific for TNFRI caused 
cytotoxicity whereas antibodies for TNFRII failed to reciprocate this. Moreover, TNFRII 
stimulation triggered cell proliferation (27). Through its DD and TRADD, TNFRI activation 
can activate the caspase-mediated pathway of apoptosis in numerous tumour cell lines (28). 
Activation of TNFRI by TNFα also induces the activation NF-B (29) and this is a negative 
regulator for apoptosis mediated by TNFRs signalling (30, 31). It has been shown that cell 
death could be augmented by the inhibition of NF-B after TNFα treatment or the specific 
activation of TNFRII (32). Pham and colleagues further demonstrated soluble TNFα-induced 
apoptosis in NF-B-deficient cells (33) which was due to JNK activation. TNFRI also contains 
a TIM domain which interacts with TRADD, TRAF1 and TRAF2 and this triggers the 
activation of receptor interacting protein kinase (RIP). RIP and TRAF2 form a complex with 
TRADD in order to induce either MAPKs which lead to NF-B, or c-Jun N-terminal kinase 
(JNK)/activator protein-1 (AP-1) activation (11). RIP is a critical player that participates in 




various biological processes for intracellular and extracellular stresses and is found to 
stimulate TNF-induced necrosis (34-37).  
TNFR-II binds to mTNFα with high affinity, thus it has been suggested that there 
must be cell-cell contact in order for TNFα to activate TNFRII effectively. TNFR-II also 
recruits TRAF1 and TRAF2, and the latter plays a critical role in activation of IKK and stress 
kinases JNK and p38. Activation of these is regulated by reactive oxygen species (ROS) 
release, which can occur either from NADPH oxidase  (Nox) or following mitochondrial 
disruption (36, 38-46). Notably, ROS induction can trigger both pro-survival and pro-
apoptotic signals; low levels of ROS activate NF-B and cell survival, yet in high amounts 
ROS appear to activate JNK and cause apoptosis or necrosis. Reports indicate that ROS is 
found to also be a critical upstream component for the activation of MAPKs, NF-B and AP-1 
and caspases, and thus many TNF-induced responses supported by findings that ROS 
regulate TNF-α-induced apoptosis/necrosis (47). In fact, JNK can induce necrosis mediated 
by TNF-stimulation by ROS augmentation, thus JNK may control the balance of TNF-
stimulated cell apoptosis versus necrosis (48). More recently mTNFα was shown to be highly 
cytotoxic to carcinoma cells due its ability to cause ROS-mediated necrosis (49). 
Interestingly, it was confirmed that apoptosis was driven by mTNFα-mediated ligation of 
TNFR –II and not –I (24, 49). Moreover, it has been reported that the inhibition of either 
ROS or JNK activity prevents the release of mitochondrial cytochrome c and caspase-3 
cleavage in response to TNFRI activation, thus demonstrating that ROS are important 
regulatory molecules in TNFα-mediated apoptosis. It should however be noted that a 
number of previous reports indicated that JNK activation is not always essential in TNF-
induced apoptosis (47, 48, 50, 51).  
 
4. The Lymphotoxin system: ligand receptor interactions and 
cell signalling  
4.1 LT receptors  
4.1.1 LTβR 
LTβR is activated by three ligands which are the two heterotrimeric LTαβ complexes 
and the homotrimeric LIGHT (31). This receptor is mainly expressed on stromal fibroblasts, 
epithelial cells, monocytes, DCs and mast cells but is absent on lymphocytes (52, 53). 
Expression of LTβR by stromal cells in the intestine is important for normal production of IgA 




after antigen recognition. Constitutive LTβR-mediated signalling leads to the development of 
autoimmune disease, including Sjogren’s disease and experimental autoimmune 
encephalomyelitis (EAE). Moreover, LTα-/- and LTβR-/- mice demonstrated a reduction in 
chemokine and adhesion molecule expression within lamina propria lymphocytes (54). 
Blocking of LT pathways in normal adult mice using soluble receptor-immunoglobulin fusion 
protein (LTβR-Ig) caused inhibition of splenic germinal centre formation and defective 
humoral responses (55). Thus, such studies using genetically modified mice indicate that 
LTβR is a key molecule involved in lymphoid organogenesis and in adaptive humoral 
immunity. Two studies using a fusion protein to inhibit LTβR signalling through LTα1β2 and 
LIGHT attenuation, have also shown that LT receptors regulate the normal development 
lymph nodes of mice offspring (56, 57). More recent studies have indicated that little LTβR 
expression is found in normal human colon tissue and adenomas, but receptor expression is 
increased on colon adenocarcinomas (58), thus indicating that LT receptor expression may 
increase during carcinogenesis.  
Activation of the LTβR receptor in vitro by either LIGHT mutein (LIGHT-R228E – 
which is mutated form of LIGHT that preferentially interacts with LTβR over HVEM) or 
agonistic anti-LTβR antibody, induces chemokine (IL-8) secretion in HEK293 and 375 
melanoma cells and inhibits the growth of 375 melanoma cells, and this appears to be due 
to differential modulation of the MAPKs signalling molecules ASK1, JNK1/2, AP1, and NF-B 
(59-62). Unlike TNFRI which activates the canonical pathway of NF-B, LTβR can activate 
both NF-B pathways (5, 11). Lukashev et al have previously demonstrated that agonistic 
multivalent pentameric anti-LTβR antibody CBE11 can reduce the growth of colon and 
cervical tumours in vivo (63). More recently, Hu et al demonstrated that LTβR activation 
using LTβR agonistic antibody BS-1 was found to induce growth inhibition (as well as NF-B 
activation) in colon carcinoma cell lines HT29 and CT26, mammary carcinoma 4T1 and soft-
tissue sarcoma CMS4 (58). Moreover, BS-1 was able to trigger the activation of caspase -8 
and -3 as well as the release of cytochrome c in tumour cells, all of which were mediated by 
LTβR activation; this provides evidence that cell growth inhibition of these tumour cells 
could be partially driven by caspase-dependent mechanism (58). The aforementioned study 
also reported that the activation of LTβR by using a different monoclonal anti-LTβR antibody 
(ACH6) suppressed the colon carcinoma metastasis in vivo (58). These findings are in 
support of previous work by Browning and colleagues demonstrating that anti-LTβR 
monoclonal antibody alone caused cell death in vitro (64). Therefore, signalling through 




LTβR either by its natural ligands or via agonistic anti-LTβR antibodies triggers cell death for 
a variety of tumour cell lines (64, 65).  
The growth of colon and cervical carcinoma cell lines in xenograft models was shown 
to be inhibited by agonistic antibody LTβR (CBE11) and this potentiated tumour responses 
to chemotherapeutic treatment (63). In vitro, however, some contradictory findings have 
been reported, as the activation of LTβR with an agonistic LTβR antibody in melanoma cell 
lines (Hs294T, SKMel5, SKMel28, and WM115) leads to the activation of the NF-B and 
enhances tumour cell proliferation (66). Mackay et al reported that activation of LTβR with 
either soluble LTα1β2 or agonistic anti-LTβR antibody (CBE11) induced activation of NF-B 
in HT29 and WiDr human adenocarcinoma lines and human lung fibroblasts WI-38 (67), but 
Browning at al demonstrated that recombinant LTα1β2 together with IFN-γ were cytotoxic 
to an array carcinoma cell lines, including HT29 and WiDr, breast adenocarcinoma cell line 
(MDA-MB-468) and cervical carcinoma (HT-3) cells (64).  
Signal transduction through LTβR involves recruitment of adaptor proteins such TRAF 
-2, -3, and -5 to the cytoplasmic tail of the receptor upon its ligation (65, 68, 69) and these 
interactions regulate TF activation. TRAF2 and TRAF5 recruitment led to NF-B activation, 
but TRAF3 was found to be a negative regulator for NF-B activation and associated with 
induction of cell death, as shown in the tumour cell line HT29 and in human embryonic 
kidney cells (HEK293T) (70), findings is an accordance with such an effect for TRAF3 in 
signalling triggered by other TNFSF members (71, 72). A study by Kim and colleagues also 
demonstrated using HeLa cells in vitro that TRAF2 and TRAF3 were recruited following the 
LIGHT/LTβR ligation and their recruitment led to the activation of NF-B and JNK (73). Bista 
and colleagues reported that TRAF3 functions as a pro-survival molecule during LTβR 
activation, through canonical and noncanonical NF-B function. In fact, LTβR-induced 
signalling complexes enhanced TRAF3 recruitment, but decreased TRAF2 recruitment which 
attenuated the phosphorylation of Ikβα and RelA genes of NF-B (74). Moreover, Chen and 
colleagues demonstrated using human hepatoma cells (Hep3BT2), HeLa and HEK293 cells 
that the activation of LTβR by using either LIGHT mutein (LIGHT-R228E) or agonistic 
monoclonal antibody anti-LTβR (clone 31G4D8) led to the recruitment of TRAF3 and TRAF5 
and the production of ROS, which in turn activated apoptosis signal-regulating kinase-1 
(ASK1) to induce caspase-dependent and caspase-independent LTβR-mediated death (59). 
Furthermore, it has been reported that a mixture of cell death features was observed 
following LTβR activation and this depended on cell type; for example, apoptosis was 




observed in the fibroblastoid line WEHI164, whereas a mixed type of cell death (apoptosis 
and necrosis) was seen in HT29 cells following LTβR activation (75).  
 
4.1.2 HVEM 
Another receptor that binds with LIGHT and LTα is the herpesvirus entry mediator 
(HVEM). This receptor is expressed by lymphoid and non-lymphoid cells, but primarily it is 
expressed transiently by NK cells and constitutively on naive CD4+ and CD8+ T cells. It is 
reported that most B cell malignancies express HVEM and these include those of B-chronic 
lymphocytic leukaemia (B-CLL), mantle cell lymphoma, acute lymphoblastic leukaemia (ALL) 
and Burkitt’s lymphoma. HVEM is also expressed by all primary myeloma cells and in plasma 
cell leukaemia (31). HVEM has dual roles acting as both a receptor and as ligand and it was 
first described as a receptor for herpes simplex virus-1 (HSV-1) glycoprotein D (HSV-gD), 
the main component of the HSV envelope for entry into human and mouse cells (76, 77). 
HVEM functions as ligand and binds the immunoglobulin (Ig) superfamily members B and T 
lymphocyte attenuator (BTLA) and CD160 (glycosylphosphatidylinositol-anchored member of 
immunoglobulin (Ig) domain protein), and expressed by many immune cells as reviewed 
recently elsewhere (78).  
It has been demonstrated that engagement of soluble LIGHT with HVEM-expressing 
U937 cells induced a weak increase in NF-B activity (79). Overexpression of HVEM in 293 
cells enhances the recruitment of adaptor proteins, TRAF -1, -2, -3, and -5, which resulted in 
activation of NF-B and AP-1 activation. By contrast, other studies demonstrated that HVEM 
activation more likely recruits TRAF2 and TRAF5, which are key mediators for the activation 
of NF-B as well as AP-1 (68, 73, 80, 81). Pasero and colleagues demonstrated that LIGHT-
mediated HVEM signalling is able to induce cell death in freshly isolated B-CLL tumour cells, 
while LTβR was not expressed or expressed at low levels. The mechanisms responsible for 
cell death in the B-CLL tumour cells related to expression of FasL, p53, Bax, Bid, Bcl-Xs and 
mitochondrial cytochrome C release (82). Interestingly, it was found that broad caspase 
inhibition via z-VAD-FMK did not prevent apoptosis, suggesting that both intrinsic and 
extrinsic pathways of apoptosis were active (82-84).  
This data suggests that despite the co-stimulatory and co-inhibitory role for HVEM 
during immune regulation, HVEM could in fact function as a tumour suppressor if utilised in 
the correct context. However, there is evidence to suggest that the way HVEM modulates 




cell fate might be indirect and more complex than the aforementioned studies suggested 
(discussed in more detail in the following sections).  
 
4.2 LT ligands  
4.2.1 LTα 
LTα is often used as a term to describe the biologically active trimer LTα3 (31, 85), 
but can exist in three different forms; soluble homotrimeric LTα3, or as two transmembrane 
heterotrimeric complexes termed LTα1β2 and LTα2β1. LTα1β2 and LTα2β1 complex 
formation occurs when soluble LTα binds to LTβ bound on the cell membrane, thus 
signalling via LTαβ-LTβR interaction requires target-effector cell contact. In addition to 
binding to TNFR (Figure 1), LTα3 may bind HVEM, although this binding has been reported 
to be with low affinity (86). LTα is secreted by activated lymphocytes, resting B cells, non-
hematopoietic and myeloid lineage cells. Like TNFα, LTα secretion has been found in some 
immortalised T cell lines including Jurkat and Hut78 (87). It is also found to be secreted 
following stimulation of Raji B lymphocytes with phorbol ester (88). It has been shown that 
when LTα is mutated at either D50N or Y108F, it will only remain as a homotrimer which is 
not able to bind TNFRI or TNFRII and is not able to induce HT29 cell apoptosis. The 
modified LTα ligand, however, co-assembled with LTβ and formed a stable ligand 
heterotrimer complex named LTαβ, which was functionally active and able to trigger cell 
death in the adenocarcinoma cell line due to a capability to bind LTβR (89). In addition, 
Browning and colleagues reported that the LTα1β2 with mutated LTα was functionally active 
on HT29 and WiDr cells (64).  
 
4.2.2 LTβ and LTαβ complexes 
The non-cleavable membrane LTβ ligand is active when homotrimeric and it ligates 
with LTβR (89). LTβ is known to be expressed in splenic naive B cells in the adult spleen, 
CD4+ T cells, and mature DCs. Evidence suggests that the expression of LTβ on these 
lymphocytes enhances the immune response, and is also responsible for antiviral immunity 
on non-lymphocytes by facilitating antigen presentation by APCs (90). LTβ remains largely 
under-researched, not only perhaps due to its lack of malignant cell toxicity, but because it 
mainly assembles with LTα in order to form membrane stable complexes of LTαβ (89).  




As in the case of LTβ, the effects of LTαβ complexes (via LTβR activation) remain 
relatively under investigated, despite the ability of LTαβ ligands to induce cytotoxic effects in 
vitro and in vivo (64, 89). The expression of both LTα1β2 and LTα2β1 complexes is 
regulated by IL-2, which leads to their induction on human peripheral blood T cells (88). 
Interestingly, LTαβ ligands exhibit differential receptor binding specificities due to the 
differences in their stoichiometry (31). In murine studies, LTαβ expression shows induction 
on splenic T cells in response to the cytokines IL-4 and IL-7 and the chemokines CCL19 and 
CCL21 (91, 92), but it is still not yet reported how this relates to humans. The interaction of 
LTαβ with its receptor LTβR is also important for the maintenance of the gut-associated 
lymphoid tissues (GALT), including, lymph nodes and Peyer’s patches and also for the 
formation of germinal centres (31, 87). This suggests that the system is important in normal 
development and immune regulation following adulthood. Some studies have looked the 
importance of the LTαβ complexes in signal transduction (31, 93-96). Of the two types of 
LTαβ membrane complexes, recombinant LTα1β2 was able to induce cell death in a range of 
carcinoma cell lines in the presence of IFN-γ (64).  
 
4.2.3 LIGHT 
Lymphotoxin-like exhibits Inducible expression and competes with herpes simplex 
virus Glycoprotein D for HVEM, HVEM being a receptor expressed on T lymphocytes (LIGHT) 
was identified and classified as a TNFL member when it showed sequence homology with 
TNFα (27%), LTα (27%), LTβ (34%), FasL (31%) and CD40L (26%) (86). LIGHT is 
constitutively expressed on myeloid cells, primary immature DCs and its expression can be 
induced on the surface of activated T cells and macrophages (79, 86, 97). LIGHT can ligate 
both LTβR and HVEM receptors (and can bind to soluble receptor DcR3) to regulate cell 
proliferation, differentiation and growth inhibition (see below). The interaction of LIGHT with 
LTβR and HVEM plays an important role in the induction of positive co-stimulatory signals 
between immune cells as reviewed in detail elsewhere (98, 99). LIGHT also plays a crucial 
role in regulating gene expression in innate and adaptive immune system against pathogens 
but also conversely may be linked to disease (autoimmunity and cancer) (reviewed in (87)).  
Work in transgenic mice showed that LIGHT is important for T cell proliferation and 
in regulation of T cell homeostasis (100). Two studies in vitro showed that LIGHT induces T 
cell proliferation, IFN-γ secretion and NF-B activation (101, 102). LIGHT also cooperates 
with CD40 ligand (CD154) contributing to DC maturation (103-105). LIGHT induces the 




expression of chemotactic molecules CCL21 and adhesion molecule (MAdCAM-1) and also 
MIG/CXCL9 and IP-10/CXCL10 most likely via LTβR signalling (106-109). The release of MIG 
and IP-10 possibly reduces tumour angiogenesis and enhances the infiltration of activated 
tumour antigen-specific T cells, which may lead to tumour regression (102, 107). A study by 
Petreaca and colleagues demonstrated in a cutaneous wound-healing model that LIGHT 
promotes apoptosis in local macrophages via LTβR in order to reduce inflammation (110). 
Conversely, however, LIGHT may enhance severe inflammation in non-lymphoid tissues 
(31). In vivo, tumours expressing LIGHT have been reported to undergo autocrine LIGHT 
mediated apoptosis thus LIGHT overall has a tumour suppressive effect (111). Other studies 
in mice have also shown that the expression of LIGHT caused activation of localised NK cells 
and the infiltration of cytotoxic CD8 T (CTL) which assisted tumour eradication (107, 112). 
Transfected murine fibrosarcoma with stable membrane LIGHT resulted in tumour rejection 
and eradication in vivo and LIGHT expression enhanced the anti-tumour response mainly by 
priming T cells (101, 107).  
Soluble LIGHT can trigger apoptosis of human tumour cells in vitro but this appears 
to require the presence of IFN-γ (111). The combination of LIGHT/IFN-γ in fact has the 
capacity to cause apoptosis of p53-normal and p53-deficient HT29 adenocarcinoma cells 
(113), MDA-MB-231 breast cancer cells (114), caspase-3 deficient MCF-7 breast cancer cells 
and human hepatoma cells (59, 101). It was recently reported that LIGHT treatment 
triggers the activation of caspase-3 with concomitant down-regulation of anti-apoptotic 
protein Bcl-2 in HCT116 colorectal carcinoma cells (115). This is in support of previous 
studies suggesting that the LIGHT/IFN-γ combination induces apoptosis via down-regulation 
of anti-apoptotic Bcl-2 family members, where the contribution of the Bcl-2 families (pro-
apoptotic and anti-apoptotic) appears to be cell type-dependent (101, 114). Some studies 
also demonstrated that LIGHT/IFN-γ induced apoptosis may be caspase-independent, as 
caspase inhibition had little effect on cell death (75). Chen and colleagues also showed that 
LIGHT treatment combined with IFN-γ drives ROS-dependent apoptosis in the human 
hepatoma line Hep3BT2 (101). There is now more evidence for a role of ROS in LT-related 
and particularly TNFα-induced apoptosis and ROS-induced death overall is increasingly 
attracting attention in the context of the TNFSF (116-118).  
Interestingly, a number of studies have suggested that the functional outcome of 
LTβR and HVEM receptor activation by LIGHT is dependent on the presence or relative 
expression levels of these receptors on the target cells. Some elegantly performed studies 
by Ware and colleagues using an HVEM-selective LIGHT mutant that cannot bind LTβR 




showed that IFN-γ assisted activation of LTβR alone is sufficient and necessary for LIGHT-
induced apoptosis in HT29 cells, and apoptosis was TRAF3-dependent (65). Interestingly, 
however, LIGHT-induced growth inhibition occurs in carcinoma cells MDA-MB-231 and HT29 
cells which express both receptors LTβR and HVEM, and also LIGHT was not cytotoxic to 
cells that expressed only one of these receptors (111). In that study, LIGHT induced growth 
inhibition in the prostate cancer cell line PC-3 which only expresses LTβR but not HVEM. 
This evidence highlighted two important points: a) LIGHT may not cause cell death for 
target cells expressing one of the receptors LTβR or HVEM, b) LIGHT engagement with 
LTβR or HVEM may trigger different biological mechanism in target cells (111). A recent in 
vitro study using HeLa and HT29 cells demonstrated that signal transduction (TRAF2 levels 
and activation of NF-B) and functional outcome (apoptosis) rely on the relative expression 
of HVEM and LTβR on the target cells (72). This is in line with studies showing that HVEM 
activation by agonistic antibodies rather than LIGHT acts to promote cell survival (119), 
whereas LTβR signalling by agonists drives cell death or cell survival in a cell type-restricted 
manner (61, 64, 67). However, such findings contrast previous studies by Pasero et al in 
cells from patients with chronic lymphocytic leukaemia, which suggested that when HVEM is 
the primary available receptor, soluble and mainly membrane-presented LIGHT promoted 
cell death. Interestingly this was found to occur via cross-talk of LIGHT-mediated signalling 
with other TNFSF members, in particular by induction of endogenous TNFα, which enhanced 
HVEM mediated cell-death (82).  
Therefore, the effect of LIGHT-induced signalling on cell fate appears complex and 
studies like those discussed above have not only suggested receptor level-related effects, 
but also, as soluble LIGHT does not bind to other TNFRs, e.g. Fas, DR4, or DR5 shown by in 
vitro binding assays (59), it is possible that indirect signalling (via cross-talk) may be 
important, too. It may therefore be possible that the HVEM and LTβR receptors can signal 
independently, cooperatively or in an antagonistic fashion in determining cell fate in the 
context of LIGHT signalling.  
 
5. The LT and CD40 ligand-receptor systems 
5.1 CD40 and its signalling and functional similarities to LT in 
regulating cell fate 
In addition to its similarities to the archetypal ligand-death receptor dyads (and 
particularly TNFα/TNFR-I/II), the LT system demonstrates strong and striking signalling and 




functional similarities to the CD40 system. CD40 was first functionally characterised in B cells 
(although originally identified as an antigen expressed in bladder carcinomas) and shares 
homology with NGFR (120). CD40 is a type I transmembrane protein with a MW 40-45 kDa 
and is constitutively expressed on activated T cells, B cells, DCs, APCs, but also at low level 
on monocytes, platelets as well as fibroblasts, epithelial, endothelial, neuronal cells, and is 
also found to be expressed by a variety of carcinomas. The ligand of CD40 is CD154 
(CD40L), a type II transmembrane protein with MW between 31-39 kDa (121). CD40L is 
predominantly expressed on activated CD4+ T cells and B cells, activated APCs (such as 
DCs) as well as activated platelets (122-124). The CD40/CD40L dyad is critical in cellular and 
humoral immune responses, and is essential for lymphocyte proliferation as well as 
differentiation and maturation. CD40/CD40L engagement mediates DC activation and the 
activated DCs promote the upregulation of other co-stimulatory molecules, for instance B7 
family members, resulting in potent production of proinflammatory cytokine in order to 
enhance productive immune responses.  
One interesting characteristic of the CD40 system is that receptor expression is not 
restricted only to normal cells but it is also expressed in both mouse and human in many 
tumour cells, including hematological malignancies, such as lymphocytic leukaemia, 
lymphoma, multiple myeloma, acute myeloid leukaemia (AML) as well as in both non-
Hodgkin’s lymphomas (NHLs) and Hodgkin’s lymphomas. Moreover CD40 is expressed on 
non-lymphoid cells where its engagement by CD40L contributes to cytokine and chemokine 
secretion and can also lead to fibroblast and endothelial cell proliferation. Although CD40 
expression is relatively low on normal epithelial cells, it is often highly expressed on solid 
tumours such as melanoma and lung cancers as well as in carcinomas of the nasopharynx, 
bladder, cervix and in ovarian cancer, although it appears to be absent from most prostate 
carcinomas (125).  
The outcome of CD40/CD40L signalling ranges from proliferation and differentiation 
to growth inhibition and cell death in a cell type- and context-dependent manner. With 
regards to its function in tumour cells, CD40 ligation has growth inhibitory effects in ovarian, 
breast, bladder (urothelial) and colorectal tumour cells in vitro when such cells were treated 
with a soluble form of CD40L or agonistic anti-CD40 antibodies (23, 126, 127). Combination 
of soluble CD40 agonist with pharmacological protein synthesis inhibitor (cycloheximide) or 
chemotherapeutic agents (e.g. cisplatin) dramatically enhanced the anti-proliferative 
properties of CD40 ligation by rendering it pro-apoptotic in various types of carcinomas (23, 
128-132).  




As in the case of the LT system, due to the lack of intrinsic kinase activity, CD40 
signalling starts with the recruitment of adaptor proteins, in particular TRAF1, TRAF2, 
TRAF3, TRAF5 and TRAF6. It has been shown that TRAF2, TRAF3 and TRAF6 bind directly 
to cytoplasmic tail of CD40 whereas TRAF1 and TRAF5 are recruited indirectly via 
interactions with TRAF2 and TRAF3, respectively. Following TRAF recruitment, signalling 
cascades triggered include the p38 MAPK, AKT, JNK/AP-1, signal transducer and activator of 
transcription 5 (STAT5) pathways and the activation of canonical and noncanonical 
pathways of NF-B. The activation of such cascades is dependent and attributed to the 
precise TRAF protein recruitment pattern. In B cells, for instance TRAF2 and MEKK1 
recruitment activates the JNK, p38 mitogen activated protein kinase (MAPK) and AKT 
pathways (133-135), whereas TRAF5 and TRAF3, are found to be required for canonical and 
noncanonical pathways of NF-B activation (71, 136, 137). Ishida and colleagues 
demonstrated that recruitment of TRAF5 via CD40 mediates the activation of NF-B (138). 
Studies in epithelial cells, where CD40 signalling is less well characterised, demonstrated the 
importance of the presence of TRAF6 in activation of canonical NF-B, p38, JNK and AKT 
following CD40 ligation and its role in anti-apoptotic signalling (139, 140). By contrast, other 
TRAFs such as TRAF3 have been implicated as mediators of CD40-induced apoptosis (127, 
141). Overall, a number of signalling and functional properties appear to be shared by CD40 
and LTβR. It has been reported that these receptors are able to induce the maturation and 
immunogenic activity for DCs, and this is because they share similarities in activating 
adaptor proteins as part of their intracellular signalling, e.g. TRAF3 induction activates the 
noncanonical NF-B pathway.  
Activation of LTβR following binding of ligands LTαβ and LIGHT, or using other 
soluble agonists, induced rapid LTβR signalling via recruitment of TRAF2, TRAF3 and TRAF5 
(69, 73). It has been suggested that the role of TRAF2 is important for the activation of NF-
B pathways (73, 81), whereas JNK activation and cell death induction through LTβR 
signalling was mediated by TRAF3. Studies using HeLa cells showed that recruitment of 
TRAF2 and TRAF3 and activation of NF-B are triggered after LTβR activation by LIGHT. 
Recruitment of TRAF2 and TRAF3 through LTβR signalling was found to be important with 
TRAF3 being critical in apoptosis (65, 70), but JNK activation in this context has not been 
reported. Moreover, two studies demonstrated that TRAF3 knockdown leads to the increase 
of protein expression of noncanonical pathway NF-B members, e.g. p100/RelB, RelB, and 
stimulation-independent activation of NIK. NIK is a kinase required for the noncanonical 
pathway activation, and the phosphorylation-mediated processing of p100/RelB into active 




form p52/RelB (74, 142, 143). NIK may act as either a pro-survival mediator by activation of 
NF-B or as a negative regulator for TRAF2 and cellular inhibitors of apoptosis 1 and 2 
(cIAP1 and cIAP2) and mediate anti-apoptotic functions (144). These observations indicate a 
similarity of LTβR signalling to other TNFRs (mainly CD40 and BAFF-R), where TRAF2 
functions as an inducer but TRAF3 acts as inhibitor of NF-B (92, 133); yet, the precise 
functional roles of TRAFs in LTβR signalling remain relatively unexplored. Moreover, HVEM 
can signal through binding to TRAF1, 2, 3 and 5 in epithelial cells (80). It was reported that 
the overexpression of HVEM contributes to the activation of JNK but signal transduction via 
HVEM activation is not fully understood (80, 145).  
It is therefore clear that the LT system shares functional similarities to other TRAF-
recruiting receptors and particularly CD40, as it can recruit one or more similar adaptor 
proteins with differential functional effects. Although more work is required to fully 
characterise such functional similarities, it is clear that understanding the precise molecular 
signature of LT and CD40 triggered signalling cascades and comparing their precise nature 
may decipher the underpinning mechanisms of the observed differential functional 
outcomes.  
 
5.2 The importance of LT receptor and CD40 cross-linking in 
determining functional outcome  
One fundamental property of the TNFSF that despite its clear importance is very 
rarely highlighted relates to how “signal quality” (i.e. the degree of receptor activation or 
cross-linking) affects or determines the outcome of receptor ligation. There is a plethora of 
reports in the literature clearly indicating that highly cross-linked agonistic antibodies, cross-
linked soluble recombinant ligands and particularly membrane-presented ligand (achieved by 
co-culture of target cells with growth-arrested, ligand-expressing third-party cells) induce a 
greater extent of carcinoma cell death in vitro in comparison to non-cross-linked agonists.  
Studies in the CD40 system have demonstrated how ligand valency, and 
consequently the extent of receptor cross-linking, can dictate cell death against survival 
signals (23). Specifically in carcinoma cell lines, membrane-presented CD40 ligand 
(mCD40L), but not soluble agonists (e.g. sCD40L), induces high level of pro-inflammatory 
cytokine secretion and causes extensive cell apoptosis (7, 23, 146), whilst remaining a 
tumour-cell specific death signal (23, 147). This is not a unique property of CD40, for 




instance it has been reported that mTNFα generates higher cytotoxicity than soluble ligand 
in certain tumour cell lines leading even to necrotic cell death (24).   
The importance of degree of TNFR cross-linking in determining functional outcome 
(23, 148) is also clear in LT-specific signalling. Triggering cell signalling through the 
activation of LTβR and HVEM has been demonstrated using various agonist formats: 
agonistic antibodies, soluble recombinant ligands (LIGHT or LTαβ) or ligation by membrane-
presented ligand LIGHT. The majority of previous studies have focused on the activation of 
LTβR, and to a lesser extent on HVEM, by soluble agonists and although activation of LT 
receptors by membrane-bound ligand (and particularly LIGHT) remains under-investigated, 
there are some studies that have utilised membrane-presented LT ligands.   
It is well established in carcinoma cell lines that cross-linking of LTβR in Hep3BT2, 
HeLa and HEK293 cells by soluble mutein LIGHT (LIGHT-R228E), which activates LTβR, and 
agonistic anti-LTβR monoclonal antibody (clone 31G4D8) were able to induce cell death in 
these cells (59, 65). Degli-Esposti and colleagues reported that cross-linking of LTβR with 
immobilized agonistic anti-LTβR monoclonal antibody (M12) induced secretion of IL-8 and 
RANTES in A375 cells, but not cell death, and similar observations were made with 
membrane-bound LTβ and LTαβ (ligands for LTβR) (61). On the other hand, Browning and 
colleagues demonstrated that immobilised agonistic monoclonal antibody anti-LTβR (CBE11) 
induced cell death efficiently for HT29, WiDr MDA-MB-468 and HT-3 better than when the 
agonist was added to cultures in non-cross-linked form (64). Importantly, the activation of 
LTβR was more enhanced when the same agonistic antibody was engineered and converted 
into an IgM-like oligomer and thus delivered in pentameric form (CBE11p). The pentameric 
agonistic antibody was shown to inhibit cell proliferation and induced cell death for HT29 in 
the presence or absence of IFN-γ to a greater extent than did the monomeric mAb form 
CBE11 (63).  
Interestingly, soluble recombinant LTα1β2 (another ligand for LTβR) was toxic when 
combined with IFN-γ in adenocarcinoma cell lines (64) and these studies by Browning and 
colleagues using different cross-linked forms of LT ligands (e.g. LTα1β2) and antibodies for 
LTβR activation have provided some evidence for the importance of the degree of receptor 
cross-linking in functional outcome for a number of cell lines in vitro. Of note also, there is 
evidence that cross-linking of HVEM receptor in CLL-derived cells (showing weak or no 
expression of LTβR) with agonistic antibody could induce downstream signalling involving 
pro- and anti-apoptotic proteins, which was more enhanced when LIGHT was presented in a 




membrane-bound form (82). Moreover, recent studies by Bechill et al have demonstrated 
that LTβR and HVEM in HeLa and HT29 cells activated by membrane-bound LIGHT (via 
target cell co-culture with CHO cells expressing LIGHT ligand) or mutant LIGHT (LIGHT-
R228E) in the presence of IFN-γ induced high levels of secretion of the CXCL10 chemokine 
(72).  
An interesting, yet related, aspect of the LT system is the clear requirement for 
synergy with IFN-γ for the induction of apoptosis. There is evidence that when LT receptor 
activation by LIGHT is combined with IFN-γ this enhanced LIGHT cytotoxicity (111), in 
accordance with studies that cross-linking LTβR alone with soluble LIGHT in presence of 
IFN-γ is sufficient to induce cell death (65). The studies by Bechill et al showing that in HeLa 
and HT29 cells LIGHT/IFN-γ induced a higher level of cytokine secretion compared with 
LIGHT treated cell alone further support this notion (72). Moreover, we now have evidence 
that cross-linking LTβR and HVEM with wild type membrane-presented LIGHT induces 
extensive cell death in carcinoma cells of various tissue origins in the absence IFN-γ 
compared with soluble agonists (Albarbar and Georgopoulos, unpublished observations).  
Therefore, there is an emerging picture that although the activation of LT receptors 
(LTβR and/or HVEM) requires the synergistic action of IFN-γ to induce adequate cytotoxicity, 
membrane-presented agonist may engage the apoptotic pathway more effectively thus 
negating the need for IFN-γ synergy. These observations on the importance of the quality of 
the signal in determining functional outcome following LT system-triggered signalling 
demonstrate intriguingly clear parallels with the mode of operation of the CD40/CD40L dyad, 
where membrane-bound agonist provides a stronger pro-apoptotic signal that overrides 
anti-apoptotic mechanisms (23, 127).  
 
6. Concluding remarks and future perspectives   
The role of the TNFLs and TNFRs in regulating cell fate in the immune system as well 
as in non-lymphoid tissues has been under extensive research over the past three decades. 
Moreover, the ability of several family members to induce death (mainly via apoptosis) 
represents a promising target for cancer therapy. Such efforts have focused mostly on death 
receptors such as TNFRI, Fas (CD95), and TRAIL-R due to their strong pro-apoptotic 
potential; however lack of tumour cell-specificity represents an obstacle in such therapeutic 
strategies. The ability of tumour-specific death induction might instead be a feature of the 
non-classical death receptors, and the LT and CD40 systems might represent better such 




targets. However, as shown in this review, it appears that such non-classical TNFR-TNFL 
dyads demonstrate more complex, cell-type and clearly context-specific capabilities, so it is 
essential that more studies delve further into the complexities of these systems.  
This complexity is evident at the signal transduction level as well as the level of 
receptor activation. For instance, there is clear difference between the ability of TNF 
agonists to trigger cell signalling when presented in a soluble versus membrane-bound form. 
Often soluble agonists lack cytotoxic potency when administrated as a single treatment 
(without synergism by co-treatment with cytokines), yet membrane-presented ligands 
appear to be superior. And although such studies have been informative to a great extent, 
the use of a variety of ligand/agonist format (soluble or membrane) between different 
studies per se often makes it difficult to form a collective and unequivocal understanding of 
the function of these ligands. Moreover, there is often a lack of consistency when it comes 
to the cell models used to study the functional role of receptor-ligand interactions. This may 
perhaps explain some of the inconsistencies evident in the literature, some of which we 
mentioned above. It is thus essential that well-characterised in vitro models (e.g. cell lines 
representative of tissues of origin) are employed to study the role of TNFRs. Equally, it is 
important that the effect of TNFR signalling is also tested in the normal counterparts of such 
cells to examine tumour cell specificity.  
In conclusion, the LT and CD40 systems display several signalling similarities as well 
as differences, but as our understanding of a) the signalling requirements, b) the cell-type 
specificity and c) the role of the quality (strength) of ligand-receptor interactions in 
determining functional outcome gradually increases, this will not only permit a better 
understanding of the biological mechanisms via which non DD domain-containing TNFRs 
induce cell death, but may also allow the design of better, i.e. more efficient, and also 
ideally tumour-specific therapeutic strategies.   
 








TNFRI, TNFRSF1A, p55-60, and CD120a, 
TNFR60 and TNFRSF1A 
Nucleated cells and all 
tissues  
DD plus TRAF2,5 TNFα, cachectin, DIF, LTα3 (149-153)  
TNFRII, CD120b, p75-80 and TNFRSF1B 
Inducible on immune cells 
and hematopoietic  
TRAF1,2,3 LTα3, TNFα, LTα2β1 (15, 150, 154, 155) 
LTβR, TNFRSF3, CD18, TNFCR, TNFRIII 
Fibroblast, epithelial, 
myeloid cells and most 
tumour cells  
TRAF2,3,5 LTβ, LTα2β1, LTα1β2, LIGHT (68-70, 74, 81, 156, 157)  
CD95, APO-1, Fas, TNFRSF6 APT1 and 
DR2 
T and B cells and 
epithelial cells 
DD plus TRAF2 
FasL, APT1LG1 CD278, and 
TNFSF6 
(158-161) 
DR3, WSL-LR, TRAMP, TR3, LARD, APO-
3, DDR3, TNFRSF12 
Activated T cells and 
tissues of thymus, spleen 
and fetal kidney 
DD plus TRAF2 
APO-3L, TWEAK, DR3LG, TL1A, 
TNFSF12 
(159, 162-165) 
DR4, Apo2, TRAILR1 and TNFRSF10A Most cells and cell lines DD TRAIL, Apo2L, TL2, TNFSF10 (166-170) 
DR5, TRAILR2, KILLER, TRICK2 and 
TNFRSF10B 
Most cells and cell lines DD TRAIL, Apo2L, TL2, TNFSF10 (167-171) 
DR6, TR-7, TNFRSF21 
Lymphoid organs, tissues 
lymphoid cells and 
tumours 
DD plus TRAF2 N.D (153, 172-174). 
DcR1, TRAILR3, TRID, Apo2, LIT and 
TNFSF10C 
Various human tissues  Absent  TRAIL, TL2, TNFSF10 (166, 171, 175-177) 
DcR2, TRAILR4, TRUNDD Various human tissues Absent  TRAIL, TL2, TNFSF10 (175, 178, 179) 
DcR3, TR6, M68, TNFRSF6B 
Monocytes, dendritic 
cells, lung tissues, 
adenocarcinomas 
Absent  FasL, LIGHT, TL1A (158, 180) 
CD27, TNFRSF7, S152 and Tp55 
T, B cell and some 
tumours 
TRAF2,3,5 CD27L, TNFSF7 and CD70 (181) 
CD30, TNFSF8 
Lymphoid cells and some 
tumours   
TRAF1,2,3,5 CD30L (150) 





Table 1  
TNFL and TNFR members 
The table summarises all known TNFRs and their cognate ligands, the cell types in which TNFRs are expressed and the adaptor 
proteins involved in signalling triggered by the receptor in each case. N.D, not determined.  
CD40, GP39, HIGM1, IMD3, TNFRSF5, 
TRAP 
T, B cells and some 
tumours  
TRAF2,3,5,6 
CD40L, CD154, CD140, HIGM1, 
TNFSF5 
(136, 138, 150, 182) 
OX40, gp34, TNFRSF4, TXGP1L,CD134, 
ACT35 
T cells and some tumours TRAF1,2,3,5,6 OX40L, TNFSF4, TXGP1 (8, 183-187)  
NGFR, P75, P75NGFR, P75NTR, CD271, 
TNFRSF16 
Nervous system, kidney, 




NGF, TNFSF16 (188) 
AITR, GITR and TNFRSF18 T cells and some tumours TRAF1,2,3,4,5 
AITRL, TL6, hGITRL and 
TNFSF18 
(143, 189-193) 
HVEM, HveA, TL1, CD270, TNFRSF14, 
ATAR, TR2 
T cells, lymphoid and 
non-lymphoid cells, and 
some tumours  
TRAF1,2,3,5 
LIGHT, LTα3, CD258, HVEM-L 
TL4, TNFSF14 
(80, 145) 
4-1BB, TNFRSF9, CD137 and ILA T cells and thymocytes TRAF1,2,3 4-1BBL and TNFSF9 (8, 194-196) 
RANK, TRANCE-R, TNFRSF11A  
Activated T cells, 
dendritic cells, lymph 
nodes 
TRAF1,2,3,5,6 
RANKL, OPGL, ODF TRANCE, 
TNFRSF11A, TNFRSF11B 
(195, 197-199)  








Figure 1 : Interactions of TNFLs and TNFRs and associated 
intracellular signalling pathways 
Schematic representation of TNFL and TNFR interactions and associated signalling, with the 
upper portion showing TNFL expression by an effector cell and lower portion showing TNFR 
expression by target cell. TNFα can be both either membrane-bound or secreted and binds to 
and activates TNFRI and TNFRII, whereas LTα3 exists in soluble homotrimeric form. LTβ is not 
shed into soluble form and can bind with LTα to form LTαβ complexes. Heterotrimeric LTα1β2 
binds LTβR and LTα2β1 binds with TNFRI, TNFRII as well as LTβR. LIGHT binds LTβR and 
HVEM as well as soluble receptor DcR3. Arrows indicate high affinity interactions, the dotted red 
arrow indicates possible binding and the dashed lines indicate binding at low affinity. TNFR-
mediated signalling is triggered via intracellular proteins associating with either the death 
domain (as for TNFRI) or a TRAF binding motif (as for CD40, LTβR). Members of the TRAF 
family are indicated: TRAF1 (purple), TRAF2 (black), TRAF3 (green), TRAF5 (red), TRAF6 
(blue). The two main signalling axes are JNK and NF-B (for precise explanations see text). 
Activation of ROS triggers ASK1 and subsequently cell death which can be either caspase-
dependent or independent. Activation of NF-B may involve canonical (classical) and 
noncanonical (alternative) pathways. The canonical pathway depends on NIK and activation of 
trimeric complex of IKKαβγ and phosphorylation of IKBα to p50/RelA; the noncanonical pathway 
of NF-B is dependent on NIK and IKKα and followed by activation of p100/RelB to p52/RelB. 
The activity of p50/RelA and p52/RelB in the nucleus leads to activation of specific gene 
transcription.  
 
Figure 2 : Mechanism of TNFLs and TNFRs shedding 
TNFLs (top) and TNFRs (bottom) are expressed in two forms, membrane-bound (via a 
transmembrane domain anchoring the protein within the cell membrane) or soluble trimeric. 




Signalling via membrane-bound forms of TNFLs requires cell-cell contact to achieve activation of 
membrane-bound forms of TNFRs to induce receptor trimerisation and trigger intracellular 
signalling. Soluble TNFLs or TNFRs are membrane-bound forms that had been cleaved into 





















6.  Micheau  O,  Tschopp  J.  Induction  of  TNF  receptor  I‐mediated  apoptosis  via  two  sequential 
signaling complexes. Cell. 2003 Jul 25;114(2):181‐90. 
7.  Engels  IH,  Totzke  G,  Fischer  U,  Schulze‐Osthoff  K,  Janicke  RU.  Caspase‐10  sensitizes  breast 






10.  Ashkenazi A. Targeting death and decoy  receptors of  the  tumour‐necrosis  factor  superfamily. 
Nature Reviews Cancer. 2002;2(6):420‐30. 
11.  Hehlgans  T,  Pfeffer  K.  The  intriguing  biology  of  the  tumour  necrosis  factor/tumour  necrosis 
factor receptor superfamily: players, rules and the games. Immunology. 2005 May;115(1):1‐20. 
12.  Moss ML,  Jin  SLC, Milla ME,  Burkhart W,  Carter HL,  Chen WJ,  et  al.  Cloning  of  a  disintegrin 




14.  Beutler B, Cerami A. The biology of  cachectin/TNF‐‐a primary mediator of  the host  response. 
Annual review of immunology. 1989;7(1):625‐55. 
15.  Cabal‐Hierro  L,  Lazo  PS.  Signal  transduction  by  tumor  necrosis  factor  receptors.  Cellular 
signalling. 2012;24(6):1297‐305. 
16.  Hernandez‐Caselles T, Stutman O. Immune functions of tumor necrosis factor. I. Tumor necrosis 
factor  induces  apoptosis  of  mouse  thymocytes  and  can  also  stimulate  or  inhibit  IL‐6‐induced 
proliferation depending on  the concentration of mitogenic costimulation. The  Journal of  Immunology. 
1993;151(8):3999‐4012. 
17.  Giroir BP, Brown  T, Beutler B. Constitutive  synthesis of  tumor necrosis  factor  in  the  thymus. 
Proceedings of the National Academy of Sciences. 1992;89(11):4864‐8. 
18.  Ruggiero V, Latham K, Baglioni C. Cytostatic and cytotoxic activity of  tumor necrosis  factor on 
human cancer cells. The Journal of Immunology. 1987;138(8):2711‐7. 
19.  Kamata H, Honda S‐i, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote 
TNFα‐induced  death  and  sustained  JNK  activation  by  inhibiting  MAP  kinase  phosphatases.  Cell. 
2005;120(5):649‐61. 
20.  Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Shepard HM. Recombinant human‐
tumor necrosis  factor‐alpha  ‐ effects on proliferation of normal and transformed‐cells  invitro. Science. 
1985 1985;230(4728):943‐5. 




21.  Fransen  L,  Ruysschaert MR,  Vanderheyden  J,  Fiers  W.  Recombinant  tumor‐necrosis‐factor  ‐ 













26.  Engelmann H, Novick D, Wallach D. Two  tumor necrosis  factor‐binding proteins purified  from 
human  urine.  Evidence  for  immunological  cross‐reactivity  with  cell  surface  tumor  necrosis  factor 
receptors. Journal of Biological Chemistry. 1990;265(3):1531‐6. 
27.  Tartaglia  LA, Weber  RF,  Figari  IS,  Reynolds  C,  Palladino MA,  Goeddel  DV.  The  two  different 
receptors  for  tumor  necrosis  factor mediate  distinct  cellular  responses.  Proceedings  of  the National 
Academy of Sciences. 1991;88(20):9292‐6. 
28.  Ashkenazi  A,  Dixit  VM.  Death  receptors:  Signaling  and  modulation.  Science.  1998  Aug 
28;281(5381):1305‐8. 
29.  Legler DF, Micheau O, Doucey MA, Tschopp  J, Bron C. Recruitment of TNF  receptor 1  to  lipid 
rafts is essential for TNFalpha‐mediated NF‐kappaB activation. Immunity. 2003 May;18(5):655‐64. 
30.  Karin M,  Lin A. NF‐kappaB  at  the  crossroads of  life  and death. Nat  Immunol.  [Review]. 2002 
Mar;3(3):221‐7. 
31.  Ware  CF.  Network  communications:  lymphotoxins,  LIGHT,  and  TNF.  Annu  Rev  Immunol. 
2005;23:787‐819. 





34.  Zhang  D,  Lin  J,  Han  J.  Receptor‐interacting  protein  (RIP)  kinase  family.  Cellular & molecular 
immunology. 2010;7(4):243‐9. 



















42.  Rothe M,  Pan M‐G, Henzel WJ,  Ayres  TM,  V Goeddel D.  The  TNFR2‐TRAF  signaling  complex 
contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 1995;83(7):1243‐
52. 
43.  Rothe M,  Sarma V, Dixit VM, Goeddel DV.  TRAF2‐mediated  activation of NF‐kappa B by  TNF 
receptor 2 and CD40. Science. 1995 Sep 8;269(5229):1424‐7. 









accumulation  of  ROS  that  mediate  prolonged MAPK  activation  and  necrotic  cell  death.  The  EMBO 
journal. 2003;22(15):3898‐909. 
48.  Lamb  JA, Ventura  JJ, Hess P, Flavell RA, Davis RJ.  JunD mediates  survival  signaling by  the  JNK 
signal transduction pathway. Mol Cell. 2003 Jun;11(6):1479‐89. 
49.  Ardestani  S,  Deskins  DL,  Young  PP. Membrane  TNF‐alpha‐activated  programmed  necrosis  is 
mediated by Ceramide‐induced reactive oxygen species. Journal of molecular signaling. 2013;8(1):12. 
50.  Liu  ZG,  Hsu  H,  Goeddel  DV,  Karin M.  Dissection  of  TNF  receptor  1  effector  functions:  JNK 
activation  is  not  linked  to  apoptosis while NF‐kappaB  activation  prevents  cell  death.  Cell.  1996 Nov 
1;87(3):565‐76. 
51.  Natoli  G,  Costanzo  A,  Ianni  A,  Templeton  DJ,  Woodgett  JR,  Balsano  C,  et  al.  Activation  of 





53.  Stopfer P, Mannel DN, Hehlgans T.  Lymphotoxin‐beta  receptor activation by  activated T  cells 
induces cytokine release from mouse bone marrow‐derived mast cells. Journal of Immunology. 2004 Jun 
15;172(12):7459‐65. 
54.  Kang H‐S, Chin RK, Wang Y, Yu P, Wang  J, Newell KA, et al. Signaling  via  LTβR on  the  lamina 
propria stromal cells of the gut is required for IgA production. Nature immunology. 2002;3(6):576‐82. 
55.  Mackay F, Majeau GR, Lawton P, Hochman PS, Browning JL. Lymphotoxin but not tumor necrosis 
factor  functions  to maintain splenic architecture and humoral  responsiveness  in adult mice. European 
journal of immunology. 1997;27(8):2033‐42. 
56.  Fava  RA,  Notidis  E,  Hunt  J,  Szanya  V,  Ratcliffe  N,  Ngam‐ek  A,  et  al.  A  role  for  the 
lymphotoxin/LIGHT  axis  in  the  pathogenesis  of  murine  collagen‐induced  arthritis.  The  Journal  of 
Immunology. 2003;171(1):115‐26. 
57.  Rennert PD, Browning  JL, Mebius R, Mackay  F, Hochman PS.  Surface  lymphotoxin alpha/beta 
complex  is  required  for  the development of peripheral  lymphoid organs. The  Journal of experimental 
medicine. 1996;184(5):1999‐2006. 
58.  Hu X, Zimmerman MA, Bardhan K, Yang D, Waller  JL,  Liles GB, et al.  Lymphotoxin  β  receptor 
mediates  caspase‐dependent  tumor  cell  apoptosis  in  vitro  and  tumor  suppression  in  vivo  despite 
induction of NF‐κB activation. Carcinogenesis. 2013;34(5):1105‐14. 





regulating  kinase  1  in  lymphotoxin‐beta  receptor‐mediated  cell  death.  J  Biol  Chem.  2003  May 
2;278(18):16073‐81. 
60.  Chang Y‐H, Hsieh S‐L, Chen M‐C, Lin W‐W. Lymphotoxin β receptor  induces  interleukin 8 gene 
expression via NF‐κB and AP‐1 activation. Experimental cell research. 2002;278(2):166‐74. 
61.  Degli‐Esposti MA, Davis‐Smith T, Din WS, Smolak PJ, Goodwin RG, Smith CA. Activation of  the 
lymphotoxin beta  receptor by  cross‐linking  induces chemokine production and growth arrest  in A375 
melanoma cells. The Journal of Immunology. 1997;158(4):1756‐62. 
62.  Hehlgans  T, Männel  DN.  Recombinant,  soluble  LIGHT  (HVEM  ligand)  induces  increased  IL‐8 
secretion  and  growth  arrest  in  A375  melanoma  cells.  Journal  of  Interferon  &  Cytokine  Research. 
2001;21(5):333‐8. 
63.  Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, et al. Targeting the lymphotoxin‐
beta  receptor  with  agonist  antibodies  as  a  potential  cancer  therapy.  Cancer  research.  2006  Oct 
1;66(19):9617‐24. 
64.  Browning JL, Miatkowski K, Sizing  I, Griffiths D, Zafari M, Benjamin CD, et al. Signaling through 
the  lymphotoxin  beta  receptor  induces  the  death  of  some  adenocarcinoma  tumor  lines.  Journal  of 
Experimental Medicine. 1996 Mar 1;183(3):867‐78. 
65.  Rooney  IA,  Butrovich  KD,  Glass  AA,  Borboroglu  S,  Benedict  CA,  Whitbeck  JC,  et  al.  The 
lymphotoxin‐β receptor is necessary and sufficient for LIGHT‐mediated apoptosis of tumor cells. Journal 
of Biological Chemistry. 2000;275(19):14307‐15. 











death  and  activation  of  nuclear  factor  kappa  B.  Proceedings  of  the  National  Academy  of  Sciences. 
1997;94(6):2460‐5. 
70.  Force WR, Cheung TC, Ware CF. Dominant negative mutants of TRAF3 reveal an important role 
for  the  coiled  coil  domains  in  cell  death  signaling  by  the  lymphotoxin‐beta  receptor.  The  Journal  of 
biological chemistry. 1997 Dec 5;272(49):30835‐40. 
71.  Hauer  J,  Püschner  S,  Ramakrishnan  P,  Simon  U,  Bongers M,  Federle  C,  et  al.  TNF  receptor 
(TNFR)‐associated  factor  (TRAF)  3  serves  as  an  inhibitor  of  TRAF2/5‐mediated  activation  of  the 
noncanonical NF‐κB pathway by TRAF‐binding TNFRs. Proceedings of the National Academy of Sciences 
of the United States of America. 2005;102(8):2874‐9. 
72.  Bechill  J, Muller WJ. Herpesvirus  entry mediator  (HVEM)  attenuates  signals mediated by  the 
lymphotoxin  β  receptor  (LTβR)  in  human  cells  stimulated  by  the  shared  ligand  LIGHT.  Molecular 
immunology. 2014;62(1):96‐103. 
73.  Kim  Y‐S,  Nedospasov,  S.  A.  &  Liu,  Z.‐G.  TRAF2  plays  a  key,  nonredundant  role  in  LIGHT‐
lymphotoxin β receptor signaling. Molecular and cellular biology. 2005;25(6):2130‐7. 
74.  Bista P, Zeng W, Ryan S, Bailly V, Browning  JL, Lukashev ME. TRAF3 controls activation of  the 
canonical  and  alternative  NFκB  by  the  lymphotoxin  beta  receptor.  Journal  of  Biological  Chemistry. 
2010;285(17):12971‐8. 




75.  Wilson CA, Browning  JL. Death of HT29 adenocarcinoma cells  induced by TNF  family  receptor 




77.  Spear  PG, Manoj  S,  Yoon M,  Jogger  CR,  Zago A, Myscofski D. Different  receptors  binding  to 
distinct  interfaces on herpes simplex virus gD can  trigger events  leading  to cell  fusion and viral entry. 
Virology. 2006 Jan 5;344(1):17‐24. 
78.  Šedý  J,  Bekiaris  V,  Ware  CF.  Tumor  Necrosis  Factor  Superfamily  in  Innate  Immunity  and 
Inflammation. Cold Spring Harbor perspectives in biology. 2014:a016279. 
79.  Harrop JA, McDonnell PC, Brigham‐Burke M, Lyn SD, Minton J, Tan KB, et al. Herpesvirus entry 
mediator  ligand (HVEM‐L), a novel  ligand for HVEM/TR2, stimulates proliferation of T cells and  inhibits 
HT29 cell growth. J Biol Chem. 1998 Oct 16;273(42):27548‐56. 
80.  Marsters  SA,  Ayres  TM,  Skubatch  M,  Gray  CL,  Rothe  M,  Ashkenazi  A.  Herpesvirus  entry 
mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the 
TNFR‐associated  factor  family  and  activates  the  transcription  factors  NF‐κB  and  AP‐1.  Journal  of 
Biological Chemistry. 1997 May 30;272(22):14029‐32. 
81.  Kuai J, Nickbarg E, Wooters J, Qiu Y, Wang J, Lin L‐L. Endogenous association of TRAF2, TRAF3, 
cIAP1,  and  Smac  with  lymphotoxin  β  receptor  reveals  a  novel mechanism  of  apoptosis.  Journal  of 
Biological Chemistry. 2003;278(16):14363‐9. 
82.  Pasero C, Barbarat B, Just‐Landi S, Bernard A, Aurran‐Schleinitz T, Rey J, et al. A role for HVEM, 
but  not  lymphotoxin‐beta  receptor,  in  LIGHT‐induced  tumor  cell  death  and  chemokine  production. 
European journal of immunology. 2009 Sep;39(9):2502‐14. 
83.  Korsmeyer SJ, Shutter  JR, Veis DJ, Merry DE, Oltvai Z. Bcl‐2/Bax: A  rheostat  that  regulates an 




85.  Ware  CF, VanArsdale  S, VanArsdale  TL. Apoptosis mediated by  the  TNF‐related  cytokine  and 
receptor families. J Cell Biochem. 1996 Jan;60(1):47‐55. 
86.  Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, Yu GL, et al. LIGHT, a new member 
of  the TNF superfamily, and  lymphotoxin alpha are  ligands  for herpesvirus entry mediator.  Immunity. 
1998 Jan;8(1):21‐30. 
87.  Gommerman  JL,  Browning  JL.  Lymphotoxin/light,  lymphoid  microenvironments  and 
autoimmune disease. Nature Reviews Immunology. 2003 Aug;3(8):642‐55. 
88.  Ware  CF,  Crowe  PD,  Grayson  MH,  Androlewicz  MJ,  Browning  JL.  Expression  of  surface 
lymphotoxin  and  tumor‐necrosis‐factor  on  activated  t‐cell,  b‐cell,  and  natural‐killer‐cells.  Journal  of 
Immunology. 1992 Dec 15;149(12):3881‐8. 
89.  Williams‐Abbott L, Walter BN, Cheung TC, Goh CR, Porter AG, Ware CF. The lymphotoxin‐α (LTα) 
subunit  is essential  for  the assembly, but not  for  the  receptor specificity, of  the membrane‐anchored 
LTα1β2 heterotrimeric ligand. Journal of Biological Chemistry. 1997;272(31):19451‐6. 
90.  Junt  T,  Tumanov  AV,  Harris  N,  Heikenwalder M,  Zeller  N,  Kuprash  DV,  et  al.  Expression  of 









92.  Luther  SA,  Bidgol A, Hargreaves DC,  Schmidt A,  Xu  Y,  Paniyadi  J,  et  al. Differing  activities  of 
homeostatic chemokines CCL19, CCL21, and CXCL12  in  lymphocyte and dendritic cell  recruitment and 
lymphoid neogenesis. Journal of Immunology. 2002 Jul 1;169(1):424‐33. 
93.  Browning  JL,  Dougas  I,  Ngamek  A,  Bourdon  PR,  Ehrenfels  BN,  Miatkowski  K,  et  al. 
Characterization  of  surface  lymphotoxin  forms  ‐  use  of  specific  monoclonal‐antibodies  and  soluble 
receptors. Journal of Immunology. 1995 Jan 1;154(1):33‐46. 
94.  Androlewicz MJ, Browning  JL, Ware  CF.  Lymphotoxin  is  expressed  as  a  heteromeric  complex 
with a distinct 33‐KDa glycoprotein on the surface of an activated human T‐cell hybridoma. Journal of 
Biological Chemistry. 1992 Feb 5;267(4):2542‐7. 
95.  Ware  C,  VanArsdale  T,  Crowe  P,  Browning  J.  The  ligands  and  receptors  of  the  lymphotoxin 
system.  Pathways for Cytolysis: Springer; 1995. p. 175‐218. 
96.  Browning JL, Androlewicz MJ, Ware CF. Lymphotoxin and an associated 33‐kDa glycoprotein are 
expressed  on  the  surface  of  an  activated  human  T  cell  hybridoma.  The  Journal  of  Immunology. 
1991;147(4):1230‐7. 
97.  Morel Y,  Schiano de Colella  JM, Harrop  J, Deen KC, Holmes  SD, Wattam TA,  et al. Reciprocal 




99.  Ware CF,  Šedý  JR. TNF  Superfamily Networks: bidirectional and  interference pathways of  the 
herpesvirus entry mediator (TNFSF14). Current opinion in immunology. 2011;23(5):627‐31. 
100.  Wang  J, Chun T, Lo  JC, Wu Q, Wang Y, Foster A, et al. The critical  role of LIGHT, a TNF  family 
member, in T cell development. J Immunol. 2001 Nov 1;167(9):5099‐105. 
101.  Tamada K, Shimozaki K, Chapoval AI, Zhai Y, Su  J, Chen S‐F, et al. LIGHT, a TNF‐like molecule, 
costimulates T cell proliferation and  is  required  for dendritic cell‐mediated allogeneic T cell  response. 
The Journal of Immunology. 2000;164(8):4105‐10. 
102.  Tamada K, Shimozaki K, Chapoval AI, Zhu G, Sica G, Flies D, et al. Modulation of T‐cell‐mediated 
immunity  in  tumor  and  graft‐versus‐host disease models  through  the  LIGHT  co‐stimulatory  pathway. 
Nature medicine. 2000;6(3):283‐9. 
103.  Duhen T, Pasero C, Mallet F, Barbarat B, Olive D, Costello RT. LIGHT costimulates CD40 triggering 
and  induces  immunoglobulin  secretion;  a  novel  key  partner  in  T  cell‐dependent  B  cell  terminal 
differentiation. European journal of immunology. 2004;34(12):3534‐41. 










108.  Farber  JM.  Mig  and  IP‐10:  CXC  chemokines  that  target  lymphocytes.  Journal  of  leukocyte 
biology. 1997;61(3):246‐57. 
109.  Sharma  S,  Yang  S‐C, Hillinger  S,  Zhu  LX, Huang M, Batra RK,  et  al.  SLC/CCL21‐mediated  anti‐
tumor responses require IFNgamma, MIG/CXCL9 and IP‐10/CXCL10. Mol Cancer. 2003;2(1):22. 
110.  Petreaca ML,  Yao M, Ware  C, Martins‐Green MM.  YOUNG  INVESTIGATOR  AWARD  ARTICLE: 
Vascular  endothelial  growth  factor  promotes  macrophage  apoptosis  through  stimulation  of  tumor 




necrosis  factor  superfamily  member  14  (TNFSF14/LIGHT).  Wound  Repair  and  Regeneration. 
2008;16(5):602‐14. 
111.  Zhai Y, Guo R, Hsu T‐L, Yu G‐L, Ni J, Kwon BS, et al. LIGHT, a novel  ligand for  lymphotoxin beta 
receptor and TR2/HVEM  induces apoptosis and suppresses  in vivo  tumor  formation via gene transfer. 
Journal of Clinical Investigation. 1998;102(6):1142. 












118.  Morgan  MJ,  Liu  Z‐g.  Reactive  oxygen  species  in  TNFα‐induced  signaling  and  cell  death. 
Molecules and cells. 2010;30(1):1‐12. 






122.  Higuchi  T,  Aiba  Y,  Nomura  T, Matsuda  J, Mochida  K,  Suzuki M,  et  al.  Cutting  edge:  ectopic 
expression  of  CD40  ligand  on  B  cells  induces  lupus‐like  autoimmune  disease.  The  Journal  of 
Immunology. 2002;168(1):9‐12. 
123.  Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller‐Berghaus G, et al. CD40 ligand 
on  activated  platelets  triggers  an  inflammatory  reaction  of  endothelial  cells.  Nature. 
1998;391(6667):591‐4. 
124.  Danese S, de la Motte C, Sturm A, Vogel JD, West GA, Strong SA, et al. Platelets trigger a CD40‐
dependent  inflammatory  response  in  the microvasculature  of  inflammatory  bowel  disease  patients. 
Gastroenterology. 2003;124(5):1249‐64. 
125.  Dallman C,  Johnson P, Packham G. Differential  regulation of  cell  survival by CD40. Apoptosis. 
2003;8(1):45‐53. 
126.  Jiang  E, He X, Chen X,  Sun G, Wu H, Wei  Y,  et  al.  Expression of CD40  in ovarian  cancer  and 
adenovirus‐mediated CD40 ligand therapy on ovarian cancer in vitro. Tumori. 2008;94(3):356. 
127.  Georgopoulos  NT,  Steele  LP,  Thomson  M,  Selby  PJ,  Southgate  J,  Trejdosiewicz  LK.  A  novel 
mechanism of CD40‐induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP‐1 activation. Cell 
Death & Differentiation. 2006;13(10):1789‐801. 
128.  Eliopoulos  AG,  Davies  C,  Knox  PG,  Gallagher  NJ,  Afford  SC,  Adams  DH,  et  al.  CD40  induces 








130.  Ghamande  S,  Hylander  BL,  Oflazoglu  E,  Lele  S,  Fanslow W,  Repasky  EA.  Recombinant  CD40 
ligand  therapy has  significant  antitumor  effects on CD40‐positive ovarian  tumor  xenografts  grown  in 
SCID mice and demonstrates an augmented effect with cisplatin. Cancer research. 2001;61(20):7556‐62. 
131.  Melichar B, Patenia R, Gallardo S, Melicharová K, Hu W, Freedman RS. Expression of CD40 and 
growth‐inhibitory  activity  of  CD40  ligand  in  ovarian  cancer  cell  lines.  Gynecologic  oncology. 
2007;104(3):707‐13. 




factor  2  (TRAF2)‐deficient  B  lymphocytes  reveal  novel  roles  for  TRAF2  in  CD40  signaling.  Journal  of 
Biological Chemistry. 2003;278(46):45382‐90. 
134.  Gallagher E, Enzler T, Matsuzawa A, Anzelon‐Mills A, Otero D, Holzer R, et al. Kinase MEKK1  is 

















141.  Elmetwali  T,  Young  LS,  Palmer  DH.  CD40  ligand‐induced  carcinoma  cell  death:  a  balance 
between  activation  of  TNFR‐associated  factor  (TRAF)  3‐dependent  death  signals  and  suppression  of 
TRAF6‐dependent survival signals. The journal of immunology. 2010;184(2):1111‐20. 





TRAF1  and  TRAF2  and  c‐IAP1  and  c‐IAP2  to  suppress  caspase‐8  activation.  Science. 
1998;281(5383):1680‐3. 
145.  Hsu H,  Solovyev  I, Colombero A,  Elliott R, Kelley M, Boyle WJ. ATAR,  a novel  tumor necrosis 
factor  receptor  family  member,  signals  through  TRAF2  and  TRAF5.  Journal  of  Biological  Chemistry. 
1997;272(21):13471‐4. 
146.  Zapata  JM,  Pawlowski  K,  Haas  E, Ware  CF,  Godzik  A,  Reed  JC.  A  diverse  family  of  proteins 













150.  Armitage RJ.  Tumor necrosis  factor  receptor  superfamily members  and  their  ligands. Current 
opinion in immunology. 1994 Jun;6(3):407‐13. 
151.  Vince JE, Pantaki D, Feltham R, Mace PD, Cordier SM, Schmukle AC, et al. TRAF2 must bind to 
cellular  inhibitors  of  apoptosis  for  tumor  necrosis  factor  (TNF)  to  efficiently  activate  NF‐κB  and  to 
prevent TNF‐induced apoptosis. Journal of Biological Chemistry. 2009;284(51):35906‐15. 
152.  Terry  Powers  JL, Mace  KE,  Parfrey H,  Lee  S‐J,  Zhang G,  Riches DW.  TNF  receptor‐1  (TNF‐R1) 
ubiquitous scaffolding and signaling protein interacts with TNF‐R1 and TRAF2 via an N‐terminal docking 
interface. Biochemistry. 2010;49(36):7821‐9. 
153.  Kitson  J, Raven T,  Jiang Y‐P, Goeddel DV, Giles KM, Pun K‐T, et al. A death‐domain‐containing 
receptor that mediates apoptosis. Nature. 1996;384(6607):372‐5. 
154.  Smith CA, Davis T, Anderson D, Solam  L, Beckmann MP,  Jerzy R, et al. A  receptor  for  tumor‐
necrosis‐factor  defines  an  unusual  family  of  cellular  and  viral‐proteins.  Science.  1990  May 
25;248(4958):1019‐23. 





ubiquitin:  TRAF3  E3  ligases  by  the  lymphotoxin‐β  receptor.  Journal  of  Biological  Chemistry. 
2010;285(22):17148‐55. 
158.  Pitti RM, MARSTERS, S. A., LAWRENCE, D. A., ROY, M., KISCHKEL, F. C., DOWD, P., HUANG, A., 














163.  Bodmer  J‐L,  Burns  K,  Schneider  P,  Hofmann  K,  Steiner  V,  Thome M,  et  al.  TRAMP,  a  novel 
apoptosis‐mediating  receptor with  sequence  homology  to  tumor  necrosis  factor  receptor  1  and  Fas 
(Apo‐1/CD95). Immunity. 1997;6(1):79‐88. 
164.  Marsters  SA,  Sheridan  JP,  Donahue  CJ,  Pitti  RM,  Gray  CL,  Goddard  AD,  et  al.  Apo‐3,  a  new 
member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis 
and NF‐κB. Current Biology. 1996;6(12):1669‐76. 









167.  Kischkel  FC,  Lawrence  DA,  Chuntharapai  A,  Schow  P,  Kim  KJ,  Ashkenazi  A.  Apo2L/TRAIL‐
dependent  recruitment  of  endogenous  FADD  and  caspase‐8  to  death  receptors  4  and  5.  Immunity. 
2000;12(6):611‐20. 
168.  van Geelen CM, Pennarun B, Le PT, de Vries EG, de  Jong S. Modulation of TRAIL  resistance  in 
colon carcinoma cells: different contributions of DR4 and DR5. BMC cancer. 2011;11(1):39. 
169.  Chaudhary  PM,  Eby M,  Jasmin A,  Bookwalter A, Murray  J, Hood  L. Death  receptor  5,  a  new 
member  of  the  TNFR  family,  and  DR4  induce  FADD‐dependent  apoptosis  and  activate  the  NF‐κB 
pathway. Immunity. 1997;7(6):821‐30. 
170.  Schneider P, Thome M, Burns K, Bodmer  J‐L, Hofmann K, Kataoka T, et  al. TRAIL  receptors 1 
(DR4) and 2 (DR5) signal FADD‐dependent apoptosis and activate NF‐κB. Immunity. 1997;7(6):831‐6. 
171.  MacFarlane  M,  Ahmad  M,  Srinivasula  SM,  FernandesAlnemri  T,  Cohen  GM,  Alnemri  ES. 
Identification and molecular  cloning of  two novel  receptors  for  the  cytotoxic  ligand TRAIL.  Journal of 
Biological Chemistry. 1997 Oct 10;272(41):25417‐20. 
172.  Pan  GH,  Bauer  JH,  Haridas  V,  Wang  SX,  Liu  D,  Yu  GL,  et  al.  Identification  and  functional 
characterization  of  DR6,  a  novel  death  domain‐containing  TNF  receptor.  FEBS  Lett.  1998  Jul 
24;431(3):351‐6. 
173.  Pan  G,  Bauer  JH,  Haridas  V,  Wang  S,  Liu  D,  Yu  G,  et  al.  Identification  and  functional 
characterization of DR6, a novel death domain‐containing TNF receptor. FEBS letters. 1998;431(3):351‐6. 
174.  Kasof GM,  Lu  JJ,  Liu D,  Speer  B, Mongan  KN, Gomes  BC,  et  al.  Tumor  necrosis  factor‐alpha 
induces the expression of DR6, a member of the TNF receptor family, through activation of NF‐kappaB. 
Oncogene. 2001;20(55):7965‐75. 
175.  Marsters  S,  Sheridan  J,  Pitti R, Huang A,  Skubatch M,  Baldwin D,  et  al. A  novel  receptor  for 
Apo2L/TRAIL contains a truncated death domain. Current Biology. 1997;7(12):1003‐6. 
176.  Degli‐Esposti MA,  Smolak  PJ, Walczak H, Waugh  J, Huang C‐P, DuBose RF,  et  al.  Cloning  and 















182.  Van den Oord  J, Maes A, Stas M, Nuyts  J, Battocchio S, Kasran A, et al. CD40  is a prognostic 
marker  in  primary  cutaneous  malignant  melanoma.  The  American  journal  of  pathology. 
1996;149(6):1953. 




183.  Mallett  S,  Fossum  S, Barclay AN. Characterization of  the MRC ox40  antigen of  activated CD4 
positive  lymphocytes‐T  ‐  a  molecule  related  to  nerve  growth‐factor  receptor.  Embo  Journal.  1990 
Apr;9(4):1063‐8. 
184.  Croft M, So T, Duan W,  Soroosh P. The  significance of OX40 and OX40L  to T‐cell biology and 
immune disease. Immunological reviews. 2009;229(1):173‐91. 
185.  Kawamata  S,  Hori  T,  Imura  A,  Takaori‐Kondo  A,  Uchiyama  T.  Activation  of  OX40  signal 
transduction pathways  leads  to  tumor necrosis  factor  receptor‐associated  factor  (TRAF) 2‐and TRAF5‐
mediated NF‐κB activation. Journal of Biological Chemistry. 1998;273(10):5808‐14. 
186.  Dürkop H, Latza U, Himmelreich P, Stein H. Expression of the human OX40  (hOX40) antigen  in 
normal and neoplastic tissues. British journal of haematology. 1995;91(4):927‐31. 













192.  Esparza  EM,  Lindsten  T,  Stockhausen  JM,  Arch  RH.  Tumor  necrosis  factor  receptor  (TNFR)‐
associated  factor  5  is  a  critical  intermediate  of  costimulatory  signaling  pathways  triggered  by 
glucocorticoid‐induced TNFR in T cells. Journal of Biological Chemistry. 2006;281(13):8559‐64. 
193.  Suvas S, Kim B, Sarangi PP, Tone M, Waldmann H, Rouse BT.  In vivo kinetics of GITR and GITR 





195.  Inoue  J‐i,  Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S, et al. Tumor necrosis  factor 
receptor‐associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Experimental 
cell research. 2000;254(1):14‐24. 




198.  Wong BR,  Josien R,  Lee  SY, Vologodskaia M,  Steinman RM, Choi Y. The TRAF  family of  signal 
transducers  mediates  NF‐κB  activation  by  the  TRANCE  receptor.  Journal  of  Biological  Chemistry. 
1998;273(43):28355‐9. 
199.  Kanazawa K, Azuma Y, Nakano H, Kudo A. TRAF5 Functions  in Both RANKL‐and TNFα‐Induced 
Osteoclastogenesis. Journal of Bone and Mineral Research. 2003;18(3):443‐50. 
 
 
